Baxalta and Medicxi lead €7m series-A for Gadeta

As part of the deal, Geeta Vemuri from Baxalta Ventures and Michèle Ollier and Giovanni Mariggi from Medicxi Ventures will join the company's supervisory board.

The fresh capital will allow the company to accelerate its programs and advance them to clinical trial stages. Gadeta expects to start a clinical trial in early 2017.

Previous funding
UK-based life science venture capital firm Medicxi Ventures and Utrecht Holdings provided seed funding for the company in 2015.

Company
Founded in 2015 and headquartered in Utrecht, Gadeta develops cancer immunotherapies based on gamma delta T cell receptors, which helps recognise metabolic changes in tumour cells and can be used for treatment of advanced malignancies.

People
Baxalta Venture - Geeta Vemuri (managing partner).
Medicxi Ventures - Giovanni Mariggi (principal); Michèle Ollier (partner).
Gadeta - Jürgen Kuball (co-founder); Mark de Boer (co-founder, CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• Benelux
• Netherlands
• Venture